scholarly journals Short-term proton pump inhibitor treatment may cause hypomagnesaemia in critically ill patients - a pilot study

2017 ◽  
Vol 64 (3) ◽  
pp. 499-501 ◽  
Author(s):  
Łukasz J. Krzych ◽  
Piotr Łój ◽  
Teresa Nowak ◽  
Wojciech Kazura ◽  
Piotr Knapik
Keyword(s):  
Pilot Study ◽  
Proton Pump Inhibitor ◽  
Critically Ill ◽  
Proton Pump ◽  
Critically Ill Patients ◽  
Short Term ◽  
Proton Pump Inhibitor Treatment ◽  
Inhibitor Treatment

Predictors of response to short-term proton pump inhibitor treatment in laryngopharyngeal reflux patients

2008 ◽  
Vol 122 (11) ◽  
pp. 1206-1212 ◽  
Author(s):  
N Siupsinskiene ◽  
K Adamonis ◽  
R J Toohill ◽  
R Sereika
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Laryngopharyngeal Reflux ◽  
Depression Scale ◽  
Response Prediction ◽  
Well Being ◽  
Short Term ◽  
Proton Pump Inhibitor Treatment ◽  
Medication Dose ◽  
Inhibitor Treatment

AbstractObjectives:To assess benefit from one and three months' empirical proton pump inhibitor treatment in patients with suspected laryngopharyngeal reflux, and to define pre-therapy factors which may predict success with short-term proton pump inhibitor treatment.Study design:Prospective, open clinical study.Materials and methods:One hundred adult out-patients with suspected laryngopharyngeal reflux were enrolled in the study. Laryngopharyngeal reflux patients underwent endoscopy and received omeprazole for three months. Efficacy of treatment was assessed at one and three months. Patients were classified as responders if their total symptom score had improved at least 50 per cent, their videolaryngoscopic score had improved by at least two points, and they were satisfied with the results. Pre-therapy factors assessed for an effect on omeprazole outcomes included: patient demographics, reflux symptoms, videolaryngoscopic scores, endoscopic findings, overall vocal dysfunction degree, self-rated voice handicap index, hospital anxiety and depression scale scores, and general well-being score.Results:Fifty-six per cent of patients were classified as responders at one month of treatment; this proportion rose to 92 per cent at three months. Those patients entering the study with a higher heartburn score showed a significant response after one month of omeprazole treatment. Non-responders were found to have significantly more anxiety than responders. Logistic regression analysis revealed these factors, plus the medication dose, as being relevant for faster response prediction. No significant association was found between pre-therapy factors and three-month response to proton pump inhibitor treatment.Conclusion:Three months of proton pump inhibitor treatment twice daily is warranted for confirming suspicion of laryngopharyngeal reflux. Baseline anxiety levels and heartburn scores, and the medication dose, may be relevant factors when predicting faster response to proton pump inhibitor treatment in carefully selected patients.

M1880 Short-Term Proton-Pump Inhibitor Treatment Increases Serum Chromogranin a Level

2009 ◽  
Vol 136 (5) ◽  
pp. A-437
Author(s):  
István Pregun ◽  
László Herszényi ◽  
Pál Miheller ◽  
Márk Juhász ◽  
Géza Nagy ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Chromogranin A ◽  
Short Term ◽  
Proton Pump Inhibitor Treatment ◽  
Inhibitor Treatment

scholarly journals When does proton pump inhibitor treatment become long term? A scoping review

2021 ◽  
Vol 8 (1) ◽  
pp. e000563
Author(s):  
Peter Fentz Haastrup ◽  
Dorte Ejg Jarbøl ◽  
Wade Thompson ◽  
Jane Møller Hansen ◽  
Jens Søndergaard ◽  
...  
Keyword(s):  
Proton Pump Inhibitor ◽  
Proton Pump ◽  
Cochrane Library ◽  
Clinical Context ◽  
Eligibility Criteria ◽  
Proton Pump Inhibitor Treatment ◽  
Common Definition ◽  
Definition Of ◽  
Inhibitor Treatment

ObjectiveProton pump inhibitor (PPI) use has risen substantially, primarily driven by ongoing use over months to years. However, there is no consensus on how to define long-term PPI use. Our objectives were to review and compare definitions of long-term PPI use in existing literature and describe the rationale for each definition. Moreover, we aimed to suggest generally applicable definitions for research and clinical use.DesignThe databases PubMed and Cochrane Library were searched for publications concerning long-term use of PPIs and ClinicalTrials.gov was searched for registered studies. Two reviewers independently screened the titles, abstracts, and full texts in two series and subsequently extracted data.ResultsA total of 742 studies were identified, and 59 met the eligibility criteria. In addition, two ongoing studies were identified. The definition of long-term PPI use varied from >2 weeks to >7 years. The most common definition was ≥1 year or ≥6 months. A total of 12/61 (20%) of the studies rationalised their definition.ConclusionThe definitions of long-term PPI treatment varied substantially between studies and were seldom rationalised.In a clinical context, use of PPI for more than 8 weeks could be a reasonable definition of long-term use in patients with reflux symptoms and more than 4 weeks in patients with dyspepsia or peptic ulcer. For research purposes, 6 months could be a possible definition in pharmacoepidemiological studies, whereas studies of adverse effects may require a tailored definition depending on the necessary exposure time. We recommend to always rationalise the choice of definition.

Sign in / Sign up

Export Citation Format

Share Document